RxDoctor Payments Data

Biju Mathews, MD

Interventional Cardiology · Titusville, FLNPI 1386692804

Payments from drug & device makers

$225,527in general payments, 2019–2025

Across 841 payments — averaging $268.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$77K
  • Novo Nordisk$76K
  • Boehringer Ingelheim$31K
  • Novartis$13K
  • Lilly USA, LLC$7K
  • Medtronic$5K
  • plus $17K from 50 others

What the payments were for

  • Consulting fees$6,1203%
  • Speaking & faculty fees$184,95882%
  • Travel & lodging$12,5276%
  • Food & beverage$21,82410%
  • Education$980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225,527 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$861,571
Medicare patients
2,168
Services billed
8,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban691$783,688
XareltoRivaroxaban613$675,487
EntrestoSacubitril/Valsartan135$182,112
Repatha SureclickEvolocumab131$106,199
MounjaroTirzepatide97$98,615
OzempicSemaglutide50$50,102
JardianceEmpagliflozin31$46,660
MultaqDronedarone Hcl18$35,003
BrilintaTicagrelor41$28,990
VascepaIcosapent Ethyl33$27,679
Praluent PenAlirocumab27$23,514
Metoprolol Succinate1,505$22,403
Rosuvastatin Calcium1,153$19,688
Repatha SyringeEvolocumab26$15,535
ClopidogrelClopidogrel Bisulfate1,073$15,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$419$783,688691 claims
Johnson & JohnsonXarelto$76,891$675,487613 claims
NovartisEntresto$13,437$182,112135 claims
Lilly USA, LLCMounjaro$6,569$98,61597 claims
Boehringer IngelheimJardiance, Pradaxa$30,687$51,88944 claims
Novo NordiskOzempic$76,028$50,10250 claims
Sanofi-aventis U.S. LLCMultaq$329$35,00318 claims
AstraZenecaBrilinta$220$28,99041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Titusville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →